Common variable immunodeficiency (CVID): Exploring the multiple dimensions of a heterogeneous disease

Annals of the New York Academy of Sciences

Volumn 1250, Issue 1, 2012, Pages 41-49

  Salzer, Ulrich ^a   Unger, Susanne ^a   Warnatz, Klaus ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

B cells; CVID; Hypogammaglobulinemia; Primary immunodeficiency; TACI

Indexed keywords

B CELL ACTIVATING FACTOR RECEPTOR; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ARTICLE; CHROMOSOME 17P; COMMON VARIABLE IMMUNODEFICIENCY; GENE LOCUS; GENE MUTATION; GENE SILENCING; GENETIC DISORDER; HLA SYSTEM; HUMAN; IMMUNOHISTOLOGY; NONHUMAN; PATIENT CARE; PHENOTYPE; SINGLE NUCLEOTIDE POLYMORPHISM; SPLENOMEGALY;

EID: 84857472967     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.2011.06377.x     Document Type: Article

References (87)

1. Giovannetti, A. et al 2007. Unravelling the complexity of T cell abnormalities in common variable immunodeficiency. J. Immunol. 178: 3932-3943.
2. Piqueras, B. et al 2003. Common variable immunodeficiency patient classification based on impaired B cell memory differentiation correlates with clinical aspects. J. Clin. Immunol. 23: 385-400.
3. Warnatz, K. et al 2002. Severe deficiency of switched memory B cells (CD27(+)IgM(-)IgD(-)) in subgroups of patients with common variable immunodeficiency: a new approach to classify a heterogeneous disease. Blood 99: 1544-1551.
4. Wehr, C. et al 2008. The EUROclass trial: defining subgroups in common variable immunodeficiency. Blood 111: 77-85.
5. Grimbacher, B. et al 2003. Homozygous loss of ICOS is associated with adult-onset common variable immunodeficiency. Nat. Immunol. 4: 261-268.
6. Castigli, E. et al 2005. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat. Genet. 37: 829-834.
7. Salzer, U. et al 2005. Mutations in TNFRSF13B encoding TACI are associated with common variable immunodeficiency in humans. Nat. Genet. 37: 820-828.
8. van Zelm, M.C. et al 2006. An antibody-deficiency syndrome due to mutations in the CD19 gene. N. Engl. J. Med. 354: 1901-1912.
9. Warnatz, K. et al 2009. B-cell activating factor receptor deficiency is associated with an adult-onset antibody deficiency syndrome in humans. Proc. Natl. Acad. Sci. U S A. 106: 13945-13950.
10. van Zelm, M.C. et al 2010. CD81 gene defect in humans disrupts CD19 complex formation and leads to antibody deficiency. J. Clin. Invest. 120: 1265-1274.
11. Kuijpers, T.W. et al 2010. CD20 deficiency in humans results in impaired T cell-independent antibody responses. J. Clin. Invest. 120: 214-222.
12. Thiel, J. et al 2011. Genetic CD21 deficiency is associated with hypogammaglobulinemia. J. Allergy Clin. Immunol. doi: 10.1016/j.jaci.2011.09.027.
13. Conley, M.E. 2009. Genetics of hypogammaglobulinemia: what do we really know? Curr. Opin. Immunol. 21: 466-471.
14. Conley, M.E. et al 2009. Primary B cell immunodeficiencies: comparisons and contrasts. Annu. Rev. Immunol. 27: 199-227.
15. Salzer, U. et al 2009. Relevance of biallelic versus monoallelic TNFRSF13B mutations in distinguishing disease-causing from risk-increasing TNFRSF13B variants in antibody deficiency syndromes. Blood 113: 1967-1976.
16. Garibyan, L. et al 2007. Dominant-negative effect of the heterozygous C104R TACI mutation in common variable immunodeficiency (CVID). J. Clin. Invest. 117: 1550-1557.
17. Mohammadi, J. et al 2009. Novel mutations in TACI (TNFRSF13B) causing common variable immunodeficiency. J. Clin. Immunol. 29: 777-785.
18. Chinen, J. et al 2011. Transmembrane activator and CAML interactor (TACI) haploinsufficiency results in B-cell dysfunction in patients with Smith-Magenis syndrome. J. Allergy Clin. Immunol. 127: 1579-1586.
19. Zhang, L. et al 2007. Transmembrane activator and calcium-modulating cyclophilin ligand interactor mutations in common variable immunodeficiency: clinical and immunologic outcomes in heterozygotes. J. Allergy Clin. Immunol. 120: 1178-1185.
20. Speletas, M. et al 2011. TNFRSF13B/TACI alterations in Greek patients with antibody deficiencies. J. Clin. Immunol. 31: 550-559.
21. Pan-Hammarstrom, Q. et al 2007. Reexamining the role of TACI coding variants in common variable immunodeficiency and selective IgA deficiency. Nat. Genet. 39: 429-430.
22. Ozcan, E. et al 2011. Toll-like receptor 9, transmembrane activator and calcium-modulating cyclophilin ligand interactor, and CD40 synergize in causing B-cell activation. J. Allergy Clin. Immunol. 128: 601-609. e1-4.
23. He, B. et al 2010. The transmembrane activator TACI triggers immunoglobulin class switching by activating B cells through the adaptor MyD88. Nat. Immunol. 11: 836-845.
24. Castigli, E. et al 2007. Transmembrane activator and calcium modulator and cyclophilin ligand interactor enhances CD40-driven plasma cell differentiation. J. Allergy Clin. Immunol. 120: 885-891.
25. Mantchev, G.T. et al 2007. TACI is required for efficient plasma cell differentiation in response to T-independent type 2 antigens. J. Immunol. 179: 2282-2288.
26. Sakurai, D. et al 2007. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 109: 2961-2967.
27. Castigli, E. et al 2005. TACI and BAFF-R mediate isotype switching in B cells. J. Exp. Med. 201: 35-39.
28. Seshasayee, D. et al 2003. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 18: 279-288.
29. von Bulow, G.U., J.M. van Deursen & R.J. Bram 2001. Regulation of the T-independent humoral response by TACI. Immunity 14: 573-582.
30. Yan, M. et al 2001. Activation and accumulation of B cells in TACI-deficient mice. Nat. Immunol. 2: 638-643.
31. Bacchelli, C. et al 2011. The C76R transmembrane activator and calcium modulator cyclophilin ligand interactor mutation disrupts antibody production and B-cell homeostasis in heterozygous and homozygous mice. J. Allergy Clin. Immunol. 127: 1253-1259. e1213.
32. Lee, J.J. et al 2010. The C104R mutant impairs the function of transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI) through haploinsufficiency. J. Allergy Clin. Immunol. 126: 1234-1241 e1232.
33. Lee, J.J. et al 2009. The murine equivalent of the A181E TACI mutation associated with common variable immunodeficiency severely impairs B-cell function. Blood 114: 2254-2262.
34. Losi, C.G. et al 2006. Mutational analysis of human BLyS in patients with common variable immunodeficiency. J. Clin. Immunol. 26: 396-399.
35. Salzer, U. et al 2008. Screening of functional and positional candidate genes in families with common variable immunodeficiency. BMC Immunol. 9: 3.
36. Tampella, G. et al 2011. Evaluation of CARMA1/CARD11 and Bob1 as candidate genes in common variable immunodeficiency. J. Investig. Allergol. Clin. Immunol. 21: 348-353.
37. Wang, H.Y. et al 2010. A custom 148 gene-based resequencing chip and the SNP explorer software: new tools to study antibody deficiency. Hum. Mutat. 31: 1080-1088.
38. Kralovicova, J. et al 2003. Fine-scale mapping at IGAD1 and genome-wide genetic linkage analysis implicate HLA-DQ/DR as a major susceptibility locus in selective IgA deficiency and common variable immunodeficiency. J. Immunol. 170: 2765-2775.
39. Finck, A. et al 2006. Linkage of autosomal-dominant common variable immunodeficiency to chromosome 4q. Eur. J. Hum. Genet. 14: 867-875.
40. Schaffer, A.A. et al 2006. Analysis of families with common variable immunodeficiency (CVID) and IgA deficiency suggests linkage of CVID to chromosome 16q. Hum. Genet. 118: 725-729.
41. Orange, J.S. et al 2011. Genome-wide association identifies diverse causes of common variable immunodeficiency. J. Allergy Clin. Immunol. 127: 1360-1367. e1366.
42. Byun, M. et al 2010. Whole-exome sequencing-based discovery of STIM1 deficiency in a child with fatal classic Kaposi sarcoma. J. Exp. Med. 207: 2307-2312.
43. Dickinson, R.E. et al 2011. Exome sequencing identifies GATA-2 mutation as the cause of dendritic cell, monocyte, B and NK lymphoid deficiency. Blood 118: 2656-2658.
44. van de Veerdonk, F.L. et al 2011. STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N. Engl. J. Med. 365: 54-61.
45. van der Burg, M. & A.R. Gennery 2011. Educational paper. The expanding clinical and immunological spectrum of severe combined immunodeficiency. Eur. J. Pediatr. 170: 561-571.
46. Al-Muhsen, S. & J. L. Casanova 2008. The genetic heterogeneity of mendelian susceptibility to mycobacterial diseases. J. Allergy Clin. Immunol. 122: 1043-1051; quiz 1052-1043.
47. Warnatz, K. et al 2006. Human ICOS deficiency abrogates the germinal center reaction and provides a monogenic model for common variable immunodeficiency. Blood 107: 3045-3052.
48. Takahashi, N. et al 2009. Impaired CD4 and CD8 effector function and decreased memory T cell populations in ICOS-deficient patients. J. Immunol. 182: 5515-5527.
49. Charles, E.D. et al 2011. Clonal B cells in patients with hepatitis C virus-associated mixed cryoglobulinemia contain an expanded anergic CD21low B-cell subset. Blood 117: 5425-5437.
50. Moir, S. et al 2001. HIV-1 induces phenotypic and functional perturbations of B cells in chronically infected individuals. Proc. Natl. Acad. Sci. U S A. 98: 10362-10367.
51. Wardemann, H. et al 2002. B-1a B cells that link the innate and adaptive immune responses are lacking in the absence of the spleen. J. Exp. Med. 195: 771-780.
52. Pillai, S. & A. Cariappa 2009. The follicular versus marginal zone B lymphocyte cell fate decision. Nat. Rev. Immunol. 9: 767-777.
53. Ochtrop, M.L. et al 2011. T and B lymphocyte abnormalities in bone marrow biopsies of common variable immunodeficiency. Blood 118: 309-318.
54. Driessen, G.J. et al 2011. B-cell replication history and somatic hypermutation status identify distinct pathophysiological backgrounds in common variable immunodeficiency. Blood 118: 6814-6823.
55. Bryant, A. et al 1990. Classification of patients with common variable immunodeficiency by B cell secretion of IgM and IgG in response to anti-IgM and interleukin-2. Clin. Immunol. Immunopathol. 56: 239-248.
56. Fischer, M.B. et al 1993. Defective interleukin-2 and interferon-gamma gene expression in response to antigen in a subgroup of patients with common variable immunodeficiency. J. Allergy Clin. Immunol. 92: 340-352.
57. Holm, A.M. et al 2005. Abnormal interleukin-7 function in common variable immunodeficiency. Blood 105: 2887-2890.
58. Fischer, M.B. et al 1994. A defect in the early phase of T-cell receptor-mediated T-cell activation in patients with common variable immunodeficiency. Blood 84: 4234-4241.
59. Paccani, S.R. et al 2005. Defective Vav expression and impaired F-actin reorganization in a subset of patients with common variable immunodeficiency characterized by T-cell defects. Blood 106: 626-634.
60. Foerster, C. et al 2010. B cell receptor-mediated calcium signaling is impaired in B lymphocytes of type Ia patients with common variable immunodeficiency. J. Immunol. 184: 7305-7313.
61. Yu, J.E. et al 2009. Toll-like receptor 7 and 9 defects in common variable immunodeficiency. J. Allergy Clin. Immunol. 124: 349-356, 356, e341-343.
62. Cunningham-Rundles, C. et al 2006. TLR9 activation is defective in common variable immune deficiency. J. Immunol. 176: 1978-1987.
63. Darce, J.R. et al 2007. Regulated expression of BAFF-binding receptors during human B cell differentiation. J. Immunol. 179: 7276-7286.
64. Treml, L.S. et al 2007. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J. Immunol. 178: 7531-7539.
65. Ng, L.G. et al 2006. BAFF costimulation of Toll-like receptor-activated B-1 cells. Eur. J. Immunol. 36: 1837-1846.
66. Acosta-Rodriguez, E.V. et al 2007. BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur. J. Immunol. 37: 990-1000.
67. Groom, J.R. et al 2007. BAFF and MyD88 signals promote a lupus like disease independent of T cells. J. Exp. Med. 204: 1959-1971.
68. Katsenelson, N. et al 2007. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur. J. Immunol. 37: 1785-1795.
69. Elenitoba-Johnson, K.S. & E.S. Jaffe 1997. Lymphoproliferative disorders associated with congenital immunodeficiencies. Semin. Diagn. Pathol. 14: 35-47.
70. Sander, C.A. et al 1992. Lymphoproliferative lesions in patients with common variable immunodeficiency syndrome. Am. J. Surg. Pathol. 16: 1170-1182.
71. da Silva, S.P. et al 2011. Lymphoid proliferations of indeterminate malignant potential arising in adults with common variable immunodeficiency disorders: unusual case studies and immunohistological review in the light of possible causative events. J. Clin. Immunol. 31: 784-791.
72. Ardeniz, O. & C. Cunningham-Rundles 2009. Granulomatous disease in common variable immunodeficiency. Clin. Immunol. 133: 198-207.
73. Taubenheim, N. et al 2005. Defined blocks in terminal plasma cell differentiation of common variable immunodeficiency patients. J. Immunol. 175: 5498-5503.
74. Bossaller, L. et al 2006. ICOS deficiency is associated with a severe reduction of CXCR5+CD4 germinal center Th cells. J. Immunol. 177: 4927-4932.
75. Crotty, S. 2011. Follicular helper CD4 T cells (TFH). Annu. Rev. Immunol. 29: 621-663.
76. Schatorje, E.J. et al 2011. Age-matched reference values for B-lymphocyte subpopulations and CVID classifications in children. Scand. J. Immunol. 74: 502-510.
77. Yong, P.L., J.S. Orange & K.E. Sullivan 2010. Pediatric common variable immunodeficiency: immunologic and phenotypic associations with switched memory B cells. Pediatr. Allergy Immunol. 21: 852-858.
78. Cunningham-Rundles, C. 2010. How I treat common variable immune deficiency. Blood 116: 7-15.
79. Llobet, M.P. et al 2009. Common variable immunodeficiency: 20-yr experience at a single centre. Pediatr. Allergy Immunol. 20: 113-118.
80. Lucas, M. et al 2010. Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J. Allergy Clin. Immunol. 125: 1354-1360. e1354.
81. Quinti, I. et al 2007. Long-term follow-up and outcome of a large cohort of patients with common variable immunodeficiency. J. Clin. Immunol. 27: 308-316.
82. Park, J.H. & A.I. Levinson 2010. Granulomatous-lymphocytic interstitial lung disease (GLILD) in common variable immunodeficiency (CVID). Clin. Immunol. 134: 97-103.
83. Daniels, J.A. et al 2007. Gastrointestinal tract pathology in patients with common variable immunodeficiency (CVID): a clinicopathologic study and review. Am. J. Surg. Pathol. 31: 1800-1812.
84. Daniels, J.A. et al 2009. Hepatitis in common variable immunodeficiency. Hum. Pathol. 40: 484-488.
85. Malamut, G. et al 2008. Nodular regenerative hyperplasia: the main liver disease in patients with primary hypogammaglobulinemia and hepatic abnormalities. J. Hepatol. 48: 74-82.
86. Ward, C. et al 2008. Abnormal liver function in common variable immunodeficiency disorders due to nodular regenerative hyperplasia. Clin. Exp. Immunol. 153: 331-337. [Epub 2008 Jul 2018].
87. Rizzi, M. et al 2011. Outcome of allogeneic stem cell transplantation in adults with common variable immunodeficiency. J. Allergy Clin. Immunol. 128: 1371-1374. e2.